| scholarly article | Q13442814 |
| P2093 | author name string | Ross JS | |
| Fletcher JA | |||
| P433 | issue | 4 | |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 237-252 | |
| P577 | publication date | 1998-01-01 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy | |
| P478 | volume | 3 |
| Q36757173 | A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis |
| Q36533813 | A comparison of image contrast with (64)Cu-labeled long circulating liposomes and (18)F-FDG in a murine model of mammary carcinoma |
| Q37049733 | A gene expression profile indicative of early stage HER2 targeted therapy response |
| Q38380070 | ABO blood groups in relation to breast carcinoma incidence and associated prognostic factors in Moroccan women |
| Q41564734 | Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer |
| Q34105959 | Anti-HER2 vaccines: new prospects for breast cancer therapy |
| Q34659512 | Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3 |
| Q92502340 | Automated detection of the HER2 gene amplification status in Fluorescence in situ hybridization images for the diagnostics of cancer tissues |
| Q41302727 | BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells |
| Q36505849 | Biological markers and response to neoadjuvant taxane-based chemotherapy in patients with locally advanced breast cancer |
| Q36615272 | Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease |
| Q36458747 | Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification |
| Q50720975 | Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series. |
| Q27355564 | Depletion of kinesin 5B affects lysosomal distribution and stability and induces peri-nuclear accumulation of autophagosomes in cancer cells |
| Q34806810 | Detection of HER2 amplification in circulating free DNA in patients with breast cancer. |
| Q43667901 | Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA. |
| Q54495025 | EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. |
| Q33811642 | ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. |
| Q54795146 | Effects of humoral immunity and calreticulin overexpression on postoperative course in breast cancer. |
| Q37302085 | Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters |
| Q87439641 | Expression of Concern |
| Q35583904 | Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics |
| Q33676758 | Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer |
| Q37521326 | Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). |
| Q37708897 | HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives |
| Q35893399 | HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. |
| Q42431264 | HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing |
| Q26822730 | HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies |
| Q43455376 | HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma |
| Q36087126 | HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy |
| Q54111164 | Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies. |
| Q36671364 | IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production |
| Q38965084 | In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. |
| Q33627164 | Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines |
| Q55091931 | Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. |
| Q40179943 | Lead sulfide near-infrared quantum dot bioconjugates for targeted molecular imaging |
| Q83237718 | Mammographic density and hormone receptor expression in breast cancer: the Multiethnic Cohort Study |
| Q36405652 | Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer |
| Q35905975 | Molecular Determinants of Prognosis in Hepatocellular Carcinoma. |
| Q26741320 | Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions |
| Q35196655 | Molecular and genetic prognostic factors of prostate cancer |
| Q33750808 | Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers. |
| Q30433423 | Molecular imaging agents: impact on diagnosis and therapeutics in oncology |
| Q40316579 | Molecular modeling of nearly full-length ErbB2 receptor. |
| Q36611996 | Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy |
| Q37089496 | Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond |
| Q26764879 | Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab |
| Q64819927 | Neurotheranostics as personalized medicines |
| Q37220528 | Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer |
| Q34281240 | Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output. |
| Q33952142 | Poly (A)+ transcriptome assessment of ERBB2-induced alterations in breast cell lines |
| Q34240339 | Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast |
| Q36245677 | Potential Therapeutic Targets in Uterine Sarcomas. |
| Q34967515 | Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer |
| Q54374707 | Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification. |
| Q42138361 | Quantification of kinase activity in cell lysates via photopatterned macroporous poly(ethylene glycol) hydrogel arrays in microfluidic channels |
| Q24646799 | Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis |
| Q36718403 | RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. |
| Q40745811 | Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. |
| Q36646681 | Role of hormonal risk factors in HER2-positive breast carcinomas |
| Q35572905 | Role of traditional and new biomarkers in breast carcinogenesis. |
| Q47282308 | Suppression of Kpnβ1 expression inhibits human breast cancer cell proliferation by abrogating nuclear transport of Her2. |
| Q51656955 | Survival and prognostic factors in small cell lung cancer. |
| Q26830496 | Targeted therapy for HER2 positive breast cancer |
| Q46254792 | Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention |
| Q35005626 | The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy |
| Q38097382 | The war on cancer: are we winning? |
| Q37628969 | Therapeutic implication of HER2 in advanced biliary tract cancer |
| Q36098453 | When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene |
| Q42851885 | relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor |
| Q51468721 | β-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis. |
Search more.